Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1
James E. Melnyk(University of California, San Francisco), Kevan M. Shokat(Howard Hughes Medical Institute)
Cited by 16
Related Papers
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
|PLoS Biology|2009|1.1k
Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S)
|Nature Chemical Biology|2022|146
KRAS is vulnerable to reversible switch-II pocket engagement in cells
|Nature Chemical Biology|2022|104
A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
|Cancer Discovery|2022|94
Brain-restricted mTOR inhibition with binary pharmacology
|Nature|2022|83